4519.T in “America Imports the World's Drug Prices”
Chugai Pharmaceutical Co., Ltd.
Chugai’s portfolio of patented oncology, immunology and rare-disease medicines leaves its blockbuster economics exposed if U.S. reimbursement is benchmarked against lower developed-market prices.
4519.T impact map — “America Imports the World's Drug Prices”
How this story travels from the headline to 4519.T’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 4519.T impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 242 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
America Imports the World's Drug Prices
US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
BEAR side — Chugai’s portfolio of patented oncology, immunology and rare-disease medicines leaves its blockbuster economics exposed if U.S. reimbursement is benchmarked against lower developed-market prices.
Read the full America Imports the World's Drug Prices storyBull side
1 story- GLP-1 Eats Everything
4519.T in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Chugai originated and licensed the oral GLP-1 agonist orforglipron to Eli Lilly, giving it licensing economics tied to a potentially large oral-obesity market.
Bear side
1 story- Viewing
4519.T in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Chugai’s portfolio of patented oncology, immunology and rare-disease medicines leaves its blockbuster economics exposed if U.S. reimbursement is benchmarked against lower developed-market prices.